In contrast to RA, it is very likely that efficacy observed in ITP by fostamatinib is driven primarily by Syk since Jak inhibitors cause thrombocytopenia and would be predicted to worsen the condition by blocking platelet survival signals [57]. The gene discussed is SYK; the disease is Thrombocytopenia.